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Abstract 
The purpose of this study was to determine the prevalence of viral RNA and HCV genotypic profile 6 
hemodialysis centers in Casablanca. A total of 630 patients were included in this survey, 194 patients of them  
have antibodies antiHCV + ; then the prevalence is 30.79% , indeed search for viral RNA by PCR  in this 
population  was detected in 105 patients , also, the  prevalence of viral RNA is 54.1%. The study of genotypic 
profile in this population showed the following distribution: the most prevalent genotype is genotype 1: subtype 
1a was found in 19 patients (18.09%); subtype 1b was found in 49 patients either (46, 66%); genotype 2a / 2c in 
27 patients (25.71%); genotype 2 in 5 patients (4.76%), 4h genotype was detected in one patient with a 
frequency of 0, 95%, genotype 4 was found in 4 patients with a frequency of 3, 80%. Indeed, extensive studies 
and large scale is needed to understand the epidemiology of HCV.  
Keywords: Hepatitis C virus, Prevalence, Genotype, Public health, Morocco genotypes in hemodialysis. 
 
1. Introduction 
Virus hepatitis c virus (HCV) was identified in 1989 as the causative agent of most of the previously called 
hepatitis (non-A non-B parenteral transmission) (Choo QL, et al. 1989), the HVC is one of five hepatitis virus 
(ABCD and E) It is a small virus belonging to the family of Flaviridae wrapped in 55-65 nm the diameter (Kaito, 
et al. 1994).  The HCV genome is a single RNA molecule of 9.6 kb positive-strand  (Penin, et al. 2004) .The 
HVC  has a high  genetic diversity, due to  the activity lack of exonuclease 5'-3’  (lack of corrective activity) 
RNA-dependent RNA polymerase  (Ogata, et al. 1991).  
The 5’UTR (5' Untranslated Region) is one of the most conserved regions of the genome with more 
than 90% homology between the sequences of different strains (Bukh, et al. 1992). Capsid coding region is also 
highly conserved from 81 to 88% homology (Simmonds, et al. 1994) . The most variable region of the genome is 
one encoding the envelope proteins E1 and E2. The sequences encoding the hypervariable regions HVR1, HVR2 
and HVR3 glycoprotein E2 may vary from 50% of a strain to the other (Choo, et al. 1991, Smith 1999, Troesch, 
et al. 2006, Weiner, et al. 1991).  
To bring order to the overall genetic diversity of HCV, a classification based on molecular 
phylogenetic  analysis of viral sequences was developed, in fact a consensus for a system of nomenclature and 
classification of variants of HCV genotypes  (Simmonds, et al. 2005). Each genotype is phylogenetically 
subdivided into a number of subtypes named alphabetically in the order of their discovery. Thus variants of HCV 
are classified into six genotypes (representing 6 genetic groups defined by phylogenetic analysis), 72 subtypes 
have been identified up to now (Simmonds, et al. 2005).  
As HCV is an RNA virus, it circulates in the host as a viral quasispecies, that is to say, a complex 
mixture and precariously variant genetically distinct but related (Martell, et al. 1992, Farci and Purcell 2000).  
In some patients infected with HCV it can be found more than one genotype, this is what we call 
mixed genotypes infection (Chen, et al. 2003, Antonishyn, et al. 2005). 
HCV genotyping is essential and help us to make epidemiological surveys, clinical and treatment 
management, indeed genotypes and subtypes vary in worldwide geographical distribution (Zein 2000). 
Genotypes 1a, 1b, 2 and 3 are more common worldwide; genotype 4 is very present in the Middle East. Genetic 
diversity contributes to the pathogenesis, genotypes 1 and 4 are more resistant than genotypes 2 or 3 to treatment 
with Interferon α plus Ribavirin.  Duration of treatment is tailored to genotype (Hadziyannis, et al. 2004, Fried, 
et al. 2002). 
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2. Materials and Methods 
The present study is a prospective, cross-sectional, multicenter epidemiological study realized.  
The purpose of this work is:  
• Assess the serological prevalence of HCV.  
• Detection of viral RNA by PCR.  
• Determine the genotypes and the distribution of types and subtypes in this population by a reverse 
hybridization assay (LIPA). 
This study includes 630 patients chronically infected by HCV and undergoing hemodialysis, in six 
hemodialysis centers in Casablanca. The epidemiological and clinical Collection has been given by the 
establishment of a questionnaire: A detailed clinical history and a survey on risk factors have been undertaken.  
The study procedure was approved by the Ethics Committee at Pasteur Institute of Morocco, patients 
involved were informed of the purpose of this survey and a consent form was signed. After the collection of 
blood in hemodialysis patients (approximately 10 ml were collected), the samples were placed in EDTA tubes, 
which are transported to the laboratory  
Molecular biology at Pasteur Institute storage, packaging has been sterilized in bags. These samples 
were centrifuged to obtain plasma which is the biological material to be used. The aliquot serum is divided into 
three tubes, one for serological tests, the other 2 for molecular analysis (PCR and Genotyping) plasmas that are 
not used immediately and were stored at -20 degrees Celsius.  
 
Serotyping: characterization of antibodies specific for different genotypes: 
The anti-HCV antibodies in serum search are carried out by ELISA (enzyme-linked immunosorbent assay) of the 
third generation.  
The subject is considered positive if the antiHCV + ELISA test is positive.  
 
The molecular tests based on the analysis of a region of the viral genome by PCR: 
Detection of HCV RNA in the serum is performed by a standard method of reverse transcription followed by a 
chain reaction amplification of DNA polymerase (RT-PCR).  
Our molecular biology laboratory is equipped with Cobas TaqMan HCV Test (Roche) [Cobas Monitor 
HCV 2.0 (Roche Diagnostics)], which allows the Detection and Quantification of HCV RNA in the serum of 
patients. 
The serum of all patients with positive serology is collected to extract RNA VIRAL according to 
manufacturer's instructions (Cobas Monitor HCV 2.0 (Roche Diagnostics)], samples of which were not revealed 
viral RNA are considered as a patients who eliminated HCV: a negative PCR.  
 
The genomic typing: characterization of polymorphism of a genome fragment  
The method most widely used to determine the genotype of HCV is the line probe assay commercially available 
(INNO-LIPA), based on specific oligonucleotides of the 5'-untranslated region (5 'untranslated region) that are 
immobilized on a nitrocellulose strip, the oligonucleotides are then probed with a 5 'UTR amplicon labeled with 
biotin, which binds to a specific bands genotype manner; the oligonucleotides are then visualized by using a 
reaction with streptavidin-peroxidase. The genotype is then identified with an algorithm model.(Stuyver, et al. 
1993) (Sandres-Saune, et al. 2003) 
In our study, genotyping was performed on all serum from HCV-RNA positive samples. 
 
3. Results 
We conducted this study with all patients (630 patients) in 6 centers hemodialysis ,  Median age is 48.33 +/-  
15.5 years, the range ages  is  8-90 years, while the mean age was 48 years, sex male / female ratio of 0.91. No 
patients included in this study are infected with HIV; two patients are co-infected with HBV. 
Statistical analysis showed that the prevalence increases with age, but this is not significant findings. 
Then, there's no correlation between HCV infection and sex.  
Among the 630 patients seeking hemodialysis antiHCV antibodies is positive for all 194 of them, 
prevalence is 30.79%. 
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Graphic 1: the frequency of seropositivity of HCV among centers of hemodialysis 
 
4. Discussion 
Search for antiHCV by ELISA in 630 patients in 6 centers antibody was positive in 194 patients a prevalence of 
30.79%, these results are similar to an earlier study conducted by our research team (Foullous.A, et al. 
2014).Then; the prevalence of antibodies antiHCV is dramatically high; which can be explained by nosocomial 
transmission associated with risk factors: duration of dialysis and blood transfusion before 1994 (Foullous.A, et 
al. 2014, Sekkat, et al. 2008, Caramelo, et al. 1994). 
Among the 194 patients; Research From viral HCV RNA revealed the detection of the viral genome in 
105 patients then the prevalence is 54.1%. 
The prevalence varies considerably from one center to another, indeed centers 1, 2 and 3 have a high 
prevalence (table 1) explained by a deficiency in structures and lack of personal manager , Centers 1 ,2 and 3 
start working before 1994 (blood transfusion problem), other centers 4, 5 and 6  are newer. These results are 
comparable to one’s found in several studies; the prevalence of Viral RNA varies from 58 to 92% of 
hemodialysis patients chronically infected with HCV antibody (Roth 1995, Stehman-Breen, et al. 1998, Espinosa, 
et al. 2001, Natov, et al. 1998, Salama, et al. 2000).  
Table 1: prevalence of viral RNA in the HCV in hemodialysis patients  
 
PCR + PCR- TOTAL PATIENT PREVALENCE 
CENTRE1 56 34 90 62,22% 
CENTRE2 23 16 39 58,97% 
CENTRE3 9 3 12 75% 
CENTRE4 8 22 30 26,6% 
CENTRE5 2 5 7 28,57% 
CENTRE6 7 9 16 43,75% 
TOTAL 105 89 194 54,1% 
Our sample was 194 patients; we have detected RNA viral in 105 patients: prevalence is 54.1%. 
In this study the results of the genotyping technique by LIPA found that genotype 1b was the most common with 
a frequency of 46.66% and the genotype 1a/1b (18.09%),genotype 2a/2c (25.71%),genotype 2 (4.76%), genotype 
4h (0.95%) and genotype 4 (3.8%).  
In Morocco, the first study operated in 1997 found that genotype 1b was predominant in the general 
population with a frequency  47.6%, followed by genotype 2a / 2c (37.1%) and genotype 1a (2, 8%), while in 
hemodialysis patients, only one genotype was found with a prevalence of 68.4% for subtype 1b and 15.8% for 
subtype 1a(Benani, et al. 1997) .  
In Moroccan general population a recent study, showed that genotypic distribution is comparable to 
ours: The results of sequencing the 5'UTR showed the presence of three genotypes 1, 2 and 4. On 174 infected 
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patients; 122 presented genotype1b (70.1%); 49 presented genotype 2 (28.2%) and (0.6%) non classified 
(Brahim, et al. 2012). 
Another study conducted by Rabat team in 2000 found that the distribution of genotypes of HCV 
genotype 1 (21, 47%), 2a/2c (13, 29%), 1a (6, 13%) and 3 (1,2%)(Cacoub, et al. 2000).  
Genotype 4 was found in 2 centers, which is  not common   in MOROCCO, it was found in 5 patients 
of 105 hemodialysis patients with a frequency of 4.75%, after an investigation ;  these patients were infected 
during their trip to  Mecca (pilgrimage).  
It seems that the prevalence and incidence of different genotypes of HCV depends on geographic 
regions and modes of transmission (Wasley and Alter 2000) . Genotypes 1, 2 and 3 are ubiquitous genotypes and 
they are most common in the world (Bhattacherjee, et al. 1995, McOmish, et al. 1994, Nousbaum, et al. 1995) , 
genotype 4 is very common in Central Africa, Egypt and Middle East(Ray, et al. 2000) . Genotype 5 is 
predominant in South Africa (Smuts and Kannemeyer 1995). While genotype 6 is present in South- East of Asia 
(Zein 2000, Pawlotsky 2003).  
 
Graphic 2: variation of HCV genotype in hemdialysis 
Results from the genotype analysis shows that the genotype 1b is most common with a 46.66% of 
frequency; genotypes 1a / 1b (18.09%), genotypes 2a / 2c (25.71%), genotypes 2 (4.76%), genotypes 4h (0.95%) 
and gynotypes 4 (3.8%). 
Determining HCV genotype is very important in order to understand the transmission way. The 
relationship between genotype and transmission way of infection is well established: patients infected by 
transfusion are more often infected with genotype 1b (Payan, et al. 2005, Laperche, et al. 2012). Patients 
intravenous drug users are mostly infected with genotype 3a (2/3 cases) and 1a (1/3 of cases) (Pawlotsky, et al. 
1995, Schroter, et al. 2004, Trimbitas, et al. 2014).  
Nowadays, the genotype of HCV remains the main predictor of sustained virologic response (Suppiah, 
et al. 2009, Tanaka, et al. 2009). With all treatments tested up to now, patients with genotypes 2 and 3 are twice 
as likely as patients with genotype 1 for a sustained virologic response (McHutchison, et al. 1998, Manns, et al. 
2001). Indeed, when using the combination of Interferon and Ribavirin, patients with genotypes 2 or 3 are 
treated for only 24 weeks, while it is recommended that patients infected with genotype 1 receive treatment for 
48 weeks. Although an inhibitor of HCV protease is added to the treatment protocol is also affected by the 
genotype (Lee, et al. 2008). 
 
5. Conclusion 
The study of viral diversity provides a better understanding of the epidemiology of HCV infection, the origin and 
dynamics of viral infections. Epidemiological studies all over the world show that the distribution of HCV 
genotype is characteristic of each region. 
In our series, the prevalence varies between 66.1% and 4.2% depending on the center, with an average 
of 30.79%, this high seroprevalence can be explained by risk factors in hemodialysis: vascular, the 
immunodepresion hemodialysis patients, blood transfusion and duration of dialysis. The detction of viral ARN 
showed an average prevalence of 54.1%. While the Results from the genotype analysis shows that the genotype 
1b is most common with a 46.66% of frequency; genotypes 1a / 1b (18.09%), genotypes 2a / 2c (25.71%), 
genotypes 2 (4.76%), genotypes 4h (0.95%) and gynotypes 4 (3.8%). The HCV have a high genetic diversity. 
This one   is caused by non attendance of exonuclease activity resulting from 5'-3 '(lack of corrective activity) of 
ARN polymérase dependent RNA, but also the high level of replication (10x12000 new HCV virions per day) 
then  a genetic variability is estimated to 1.9x10000 per site per year(Ogata, et al. 1991, Smith, et al. 1997, 
Neumann, et al. 1998) .  
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This variability is involved in treatment response, it’s one main obstacles development of a vaccine, 
determing HCV genotype is very important in order to understand the transmission way 
Genotyping is essential since genotypes 1 and 4 are more resistant to treatment than genotypes 2 or 3 
with treatment combination pegylated Interferon α (pegIFNα) plus Ribavirin (RBV) and also the duration of 
treatment is tailored to each genotype.  
Other studies should be undertaken to study the dynamics of change over time and to identify 
mutations in the protein coding region of the capsid in order to understand the mechanisms of viral persistence 
and resistance to antiviral drugs and to study the geographical distribution of genotypes and subtypes circulating 
HCV in different hemodialysis centers. 
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